FDA Officially Establishes the Oncology Center of Excellence, Names Richard Pazdur, MD, as Director
Today, the U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement:
“Today the U.S. Food and Drug Administration is establishing the Oncology Center of Excellence (OCE) and appointing Richard Pazdur, MD, as its Director. This will make oncology the first disease area to have a coordinated clinical review of drugs, biologics, and devices across the agency’s three medical product centers.
“The FDA is taking important steps to formalize the structure and implementation of the OCE as part of its overarching effort to better address the needs of cancer patients, through reorganization within the FDA’s Office of Medical Products and Tobacco.
“While the review criteria and application requirements for medical products, as well as the work of review staff in the centers will not change, uniting experts to collaborate on the clinical review of oncology products will enhance the agency’s work in approving safe and effective cancer products.
“In addition, the FDA’s OCE will improve the agency’s ability to advance oncology-related regulatory science and policy and streamline stakeholder engagement.”
The OCE was established as part of the National Cancer Moonshot Initiative. Dr. Pazdur previously served as Director of the Office of Hematology and Oncology Products (OHOP) in the FDA’s Center for Drug Evaluation and Research and will continue to serve in OHOP as Acting Director.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
